Cardiomyopathies: 2024 Wrap Up

Cardiology 2024 Year in Review

A. Masri

PET Imagining in Cardiac Amyloidosis

NYU Langone

S. Dorbala

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Patient Perspective: Cardiac Amyloidosis

Scripps Health

M. Nichols

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Heart Failure with Preserved Ejection Fraction: Current Perspectives…

American College of Cardiology

S. Shah

Cardiac Amyloidosis: An Overlooked but Treatable Cause of HFpEF

Inova Heart and Vascular Institute - Advanced Heart Failure Symposium

SOHO 2022: Amyloidosis - Update and How To Use Novel Agents

SOHO 2022 Tenth Annual Meeting

S. Lentzsch

Amyloidosis Types and Pathophysiology

Houston Methodist

B. Trachtenberg

How to Detect and Treat Heart Failure with Preserved Ejection Fracti…

Houston Methodist DeBakey Heart and Vascular Center

Extended Anticoagulation for VTE

Jeffrey Weitz

New Medications for Heart Failure: SGLT2 Inhibitors and Vericiguat. …

American Heart & Vascular Institute

M. Kittleson

ISCHEMIA Trial: Are We Overusing Cardiac Stents? Is Revascularizatio…

American Heart & Vascular Institute

B. Reddy

Emerging Therapies in Cardiac Amyloidosis

NYU Langone

M. Hanna

Diabetes and Heart Failure: The New Frontier

Mount Sinai Advanced Innovations in Heart Failure Symposium 2019

E. Braunwald

The CCM Solution: How Does it Work and What Does it Do?

CCM® Therapy

N. Varma

New Diagnostic and Treatment Strategies in Cardiac Amyloidosis

Canadian Collaborative Research Network

M. Davis